Evidence map›Paper›PMID 31862243›Full record

ReviewTrends in molecular medicine2020

Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.

Amit Bar-Or, Michael P Pender, Rajiv Khanna, Lawrence Steinman, Hans-Peter Hartung, Tap Maniar, Ed Croze, Blake T Aftab, Gavin Giovannoni, Manher A Joshi

Erratum issuedOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 156 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed, 1 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

156 citing papers in PubMed, 1 synthesis or guideline pooled it, 264 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 4 countries.

Amit Bar-OrCenter for Neuroinflammation and Experimental Therapeutics, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael P PenderFaculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
Rajiv KhannaCentre for Immunotherapy and Vaccine Development, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Lawrence SteinmanDepartment of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA.
Hans-Peter HartungDepartment of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Tap ManiarClinical Development, Torque Therapeutics, Boston, MA, USA.
Ed CrozeIRIS-Bay, San Francisco, CA, USA. Electronic address: ed.croze@iris-bay.com.
Blake T AftabPreclinical Science and Translational Medicine, Atara Biotherapeutics, South San Francisco, CA, USA.
Gavin GiovannoniBlizard Institute, Queen Mary University London, Barts and the London School of Medicine, London, UK.
Manher A JoshiMedical Affairs, Atara Biotherapeutics, South San Francisco, CA, USA.
Atara Biotherapeutics (United States) · USBay Institute · USHeinrich Heine University Düsseldorf · DEQIMR Berghofer Medical Research Institute · AUQueen Mary University of London · GBStanford Medicine · USTorque (United States) · USUniversity of Pennsylvania · USUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New treatments for multiple sclerosis (MS) focused on B cells have created an atmosphere of excitement in the MS community. B cells are now known to play a major role in disease, demonstrated by the highly impactful effect of a B cell-depleting antibody on controlling MS. The idea that a virus may play a role in the development of MS has a long history and is supported mostly by studies demonstrating a link between B cell-tropic Epstein-Barr virus (EBV) and disease onset. Efforts to develop antiviral strategies for treating MS are underway. Although gaps remain in our understanding of the etiology of MS, the role, if any, of viruses in propagating pathogenic immune responses deserves attention.

Indexed as

AnimalsB-LymphocytesEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansImmunotherapyMultiple Sclerosiscell-based therapiesEpstein–Barr virusimmune evasionmultiple sclerosisocrelizumabvaccination

Identifiers

PMID31862243
PMCPMC7106557
OpenAlexW2994779767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.